Strides Pharma completed the acquisition of an additional stake in Fairmed Healthcare from Duke Capital for €11.4m.

Strides Pharma, a pharmaceutical company, completed the acquisition of an additional stake in Fairmed Healthcare, a provider of generic prescription medicines, over-the-counter pharmaceuticals, dermocosmetics and dietary supplements, from Duke Capital, a provider of hybrid capital solutions, for €11.4m. "We are proud to have supported Fairmed during a crucial time in the development of its product portfolio. Our capital injection empowered its management team to achieve their strategic objectives without burdening the business with loss of control or refinancing risk, underscoring our commitment to facilitating growth and success for our partners. We are pleased to build on our track record of successfully delivering profitable exits and are excited to see Fairmed and Strides deliver on the next phase of their European strategy. We look forward to continuing to deploy capital into other promising opportunities," Neil Johnson, Duke Capital CEO.